



OncoBREAST Dx - Final Report

Patient Information

Identification Data

HRN: BRE00000273
ID Card: Unknown

Personal Data

Age (years): 47

Comorbidities

Atherosclerosis: No
Chronic Liver Disease: No
Diabetes Mellitus 1 or 2: No
Jaundice: No
Renal Failure: No

General Biochemistry

Creatinine (mg/dL): 1.00
ASAT (U/L): 8.00
ALAT (U/L): 12.00
GGT (U/L): 7.00
Total Bilirubin (mg/dL): 1.00
Hemolized Sample: No

Serum Tumor Markers

CA 15.3 (U/mL): 19.70
CEA (ng/mL): 1.60
EGFR (ng/mL): 5.00
NGAL (ng/mL): 4.60
NSE (ng/mL): 7.00

Blood Drawn Realization

Blood Drawn Date: 11-10-2017

Urine Tumor Markers

8-OHdG (ng/mL): 11.10

Urine Drawn Realization

Urine Drawn Date: 11-10-2017

Lifestyle

Smoking: Currently

Outcome

Results

Some Tumor Markers are outside the reference range and suggest malignancy.



Comments

In absence of comorbidities that are well-known source of False Positive (FP) in healthy patients by increasing some Tumor Markers levels, whole Tumor Markers levels suggest malignancy.

Conclusions

WE SUGGEST BREAST CANCER. THE 2016 ICD-10-CM DIAGNOSIS CODE IS C50 (MALIGNANT NEOPLASM OF BREAST).

This report has been generated from the data entered on 19-12-2017 10:55:02 UTC/GMT.

Disclaimer

This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Breast Cancer has been developed for the exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm bears a Sensitivity = 82.3%, Specificity = 85.7%. Please note, negativity of the Tumor Markers does not exclude at 100% the possibility of a malignant epithelial tumor.

Bioprognos SL
Benet Mateu, 40 - 08034 Barcelona (Spain)
Email: info@bioprognos.com
Website: www.bioprognos.com



Technical Responsible
Lorena Lendinez
Chief Scientific Officer
Bioprognos SL